[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567277":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":37,"centralContacts":42,"locations":34,"responsibleParty":51,"collaborators":55,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":34,"enrollmentInfo":70,"targetDuration":34,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":84,"whyStopped":34,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":34},{"fullName":5,"class":6},"Université Libre de Bruxelles","OTHER",[8,14,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo","PLACEBO_COMPARATOR","Olive oil",[13],"Dietary Supplement: Placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"Predominant EPA","ACTIVE_COMPARATOR","4 capsules MorEPA plus (Minami Neslé) daily; 590 mg EPA (20:5 n-3) and 130 mg DHA (22:6 n-3)\u002Fgels Total: 2360 mg EPA + 520 mg DHA daily; Total in n-3: 2880 mg daily",[19],"Dietary Supplement: Long chain polyunsaturated Omega-3",{"label":21,"type":16,"description":22,"interventionNames":23},"Predominant DHA","4 capsules MorDHA (Minami Neslé) daily; 480 mg DHA (22:6 n-3) and 104 mg EPA (20:5 n-3)\u002Fgels Total: 1920 mg DHA + 416 mg EPA daily; Total in n-3: 2336 mg daily",[19],{"label":25,"type":16,"description":26,"interventionNames":27},"EPA and DHA combined","2 capsules Mor DHA (total 1220 mg DHA) + 2 soft gels Mor EPA (total 1388 mg EPA): 2608 mg daily",[19],[29,35],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DIETARY_SUPPLEMENT","Long chain polyunsaturated Omega-3","2 capsules of fatty acids in the morning and 2 capsules in the evening except the first day, 4 soft gels in a single administration in the morning, ± 2,6 g\u002Fd",[25,21,15],null,{"type":30,"name":9,"description":11,"armGroupLabels":36,"otherNames":34},[9],[38],{"name":39,"affiliation":40,"role":41},"Karim Zouaoui Boudjeltia, PhD","Laboratory of Experimental Medicine","STUDY_DIRECTOR",[43,48],{"name":44,"role":45,"phone":46,"phoneExt":34,"email":47},"Kéziah Korpak, Medical Doctor","CONTACT","003271921490","keziah.korpak@ulb.be",{"name":39,"role":45,"phone":49,"phoneExt":34,"email":50},"003271924705","karim.zouaoui.boudjeltia@ulb.be",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":34,"oldOrganization":34},"PRINCIPAL_INVESTIGATOR","Korpak Kéziah","Korpak Kéziah, medical doctor",[56,58],{"name":57,"class":6},"University of Mons",{"name":59,"class":6},"Université Catholique de Louvain","100567277","effects-of-n3-lc-pufas-on-inflammatory-immune-and-senescence-features-in-polyvascular-older-subjects-omsage-100567277",false,"NCT06666101","Effects of n3 LC PUFAs on Inflammatory, Immune and Senescence Features in Polyvascular Older Subjects (OMSAGE)","Immunomodulatory Effects of Polyunsaturated ω-3 Fatty Acids in Old Patients With Polyvascular Disease: a Double-blind, Randomized, Controlled, Factorial 2x2 Trial (\"OMEGA3\" Study)","OMSAGE","Inclusion Criteria:\n\n* ≥ 75 years old\n* Patients with polyvascular disease in cases of vascular lesions in ≥2 disease territories or any combination of coronary, peripheral, or carotid artery disease.\n* Able to comply with the requirements of the study protocol\n* Signed informed consent form approved by the ethical committee\n* No illness or event within 2 months prior to inclusion (hospitalization, trauma, active cancer, infection, acute failure of chronic disease, surgical intervention)\n* No history of multiple and\u002For severe allergies to drugs or foods\n* No consumption of fish oil or omega-3 fatty acid supplements within 2 months prior to inclusion\n* No consumption of more than 500 mg\u002Fday of dietary omega-3 fatty acids (questionnaire)\n* No intake of anti-inflammatory or corticosteroid medication within 2 weeks prior to inclusion\n* Able and authorized to take a pill\n* No intervention planned in the months following the start of the study\n\nExclusion Criteria:\n\n* Inflammatory syndrome (CRP \\>10 mg\u002Fl) on day 0 and day 7\n* Acute illness or event during the time of intervention","ALL","75 Years",{"count":71,"type":72},80,"ESTIMATED","INTERVENTIONAL",[75],"NA","The objectives is to evaluate the effect of omega-3 fatty acids in old participants with polyvascular disease on immune parameters and inflammatory mediators at different times. Three modalities of administration of omega-3 will be compared with a placebo (olive oil): predominant EPA (Eicosapentaenoic acid), predominant DHA (doxosahexaenoic acid), and combinaison of both. This study will measure the level of omega3 fatty acids in this population 4 hours after taking, on the 7th day, on the 21th day of administration and 1 month after administration.",[78],"Polyvascular Disease",[80,81,82,83],"fatty acid, omega 3","immune response","inflammatory mediators","macrophage polarisation","NOT_YET_RECRUITING","2024-10-28",{"date":87,"type":88},"2024-10-30","ACTUAL",{"date":90,"type":72},"2024-11-04",{"date":92,"type":72},"2025-12-31",{"name":5,"class":6}]